PL3226843T3 - Kompozycje przeciwnowotworowe - Google Patents

Kompozycje przeciwnowotworowe

Info

Publication number: PL3226843T3
Authority: PL; Poland
Prior art keywords: anticancer compositions; anticancer; compositions
Prior art date: 2014-12-05

Application number

PL15820351T

Other languages

English (en)

Inventor

Geert Verreck

Original Assignee

Aragon Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-03

Publication date

2021-12-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3226843(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-03 Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.

2021-12-13 Publication of PL3226843T3 publication Critical patent/PL3226843T3/pl

Links

230000001093 anti-cancer Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Processes Of Treating Macromolecular Substances (AREA)

PL15820351T 2014-12-05 2015-12-03 Kompozycje przeciwnowotworowe PL3226843T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14196605		2014-12-05
PCT/US2015/063671 WO2016090105A1 (en)	2014-12-05	2015-12-03	Anticancer compositions
EP15820351.3A EP3226843B1 (en)	2014-12-05	2015-12-03	Anticancer compositions

Publications (1)

Publication Number	Publication Date
PL3226843T3 true PL3226843T3 (pl)	2021-12-13

Family

ID=52006907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15820351T PL3226843T3 (pl)	2014-12-05	2015-12-03	Kompozycje przeciwnowotworowe

Country Status (34)

Country	Link
US (3)	US10285948B2 (pl)
EP (2)	EP3226843B1 (pl)
JP (1)	JP6830892B2 (pl)
KR (1)	KR102387089B1 (pl)
CN (1)	CN106999432A (pl)
AR (1)	AR102925A1 (pl)
AU (1)	AU2015358497B2 (pl)
CA (1)	CA2969675C (pl)
CL (1)	CL2017001373A1 (pl)
CO (1)	CO2017005574A2 (pl)
CR (1)	CR20170218A (pl)
CY (1)	CY1124504T1 (pl)
DK (1)	DK3226843T3 (pl)
EA (1)	EA201791251A1 (pl)
ES (1)	ES2883187T3 (pl)
HR (1)	HRP20211140T1 (pl)
HU (1)	HUE054935T2 (pl)
IL (1)	IL252325A0 (pl)
LT (1)	LT3226843T (pl)
MA (1)	MA41111B1 (pl)
MD (1)	MD3226843T2 (pl)
MX (1)	MX381829B (pl)
MY (1)	MY192931A (pl)
NI (1)	NI201700068A (pl)
PH (1)	PH12017500979A1 (pl)
PL (1)	PL3226843T3 (pl)
PT (1)	PT3226843T (pl)
RS (1)	RS62421B1 (pl)
SG (1)	SG11201704386VA (pl)
SI (1)	SI3226843T1 (pl)
SM (1)	SMT202100454T1 (pl)
TW (1)	TWI709403B (pl)
UA (1)	UA123538C2 (pl)
WO (1)	WO2016090105A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2013323861C1 (en)	2012-09-26	2024-05-02	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MA41111B1 (fr)	2014-12-05	2021-09-30	Aragon Pharmaceuticals Inc	Compositions anticancéreuses
MX2020003845A (es)	2017-10-16	2020-11-06	Aragon Pharmaceuticals Inc	Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
WO2020144646A1 (en)	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Apalutamide dispersed in applesauce for treating prostate cancer
CA3128331C (en)	2019-01-30	2024-06-18	Margaret K. YU	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
JP2022524289A (ja)	2019-01-30	2022-05-02	ヤンセンファーマシューティカエヌ．ベー．	分子サブタイプに基づいて前立腺癌を治療する方法
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
JP2023500935A (ja)	2019-11-04	2023-01-11	アラゴンファーマシューティカルズ，インコーポレイテッド	重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
WO2021245285A1 (en)	2020-06-05	2021-12-09	Janssen Pharmaceutica Nv	Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en)	2020-09-04	2022-03-10	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2022195407A1 (en)	2021-03-19	2022-09-22	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2023152611A1 (en)	2022-02-11	2023-08-17	Aragon Pharmaceuticals, Inc.	Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en)	2022-04-26	2023-11-02	Aragon Pharmaceuticals, Inc.	Approved drug products and methods for treating prostate cancer
WO2024189186A1 (en)	2023-03-16	2024-09-19	Bayer Consumer Care Ag	Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2132449C (en)	1992-03-31	2002-09-10	Susan E. Barrie	17 - substituted steroids useful in cancer treatment
ATE364374T1 (de)	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20030068374A1 (en)	2000-02-21	2003-04-10	Shigeru Kamei	Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
IL157389A0 (en)	2001-02-27	2004-05-12	Astrazeneca Ab	A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament
SK12032003A3 (sk)	2001-04-02	2004-03-02	Astrazeneca Ab	Farmaceutická formulácia obsahujúca 4'-kyano-alfa', alfa', alfa'-trifluór-3-(4-fluórfenylsulfonyl)-2-hydroxy-2- metylpropiono-m-toluidín a PVP
EP1399190B1 (en)	2001-06-22	2010-09-08	Bend Research, Inc.	Pharmaceutical compositions comprising low-solubility and acid-sensitive drugs and neutralized acidic polymers
SE0103424D0 (sv)	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
WO2003063821A2 (en)	2002-02-01	2003-08-07	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
JPWO2003077827A1 (ja)	2002-03-19	2005-07-14	日本新薬株式会社	医薬固体分散体の製造方法
CN1878539B (zh)	2003-12-15	2010-06-23	科学与工业研究委员会	含苦味药物和pH敏感性聚合物的掩味的药物组合物
PT3412290T (pt)	2006-03-27	2021-04-19	Univ California	Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
MA33028B1 (fr) *	2009-04-03	2012-02-01	Plexxikon Inc	Compositions et utilisations associees
CA2787083C (en)	2010-02-16	2018-05-22	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
US10071945B2 (en)	2011-06-15	2018-09-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en)	2012-03-21	2015-02-05	Emphascience, Inc.	Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) *	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
EA028791B1 (ru) *	2012-06-07	2017-12-29	Арагон Фармасьютикалз, Инк.	Кристаллическая форма модулятора андрогенных рецепторов
US10668156B2 (en)	2012-06-22	2020-06-02	Basf Se	Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
JP6215945B2 (ja)	2012-08-24	2017-10-18	ダウグローバルテクノロジーズエルエルシー	新規ヒドロキシアルキルメチルセルロースアセテートサクシネート
PL3725778T3 (pl) *	2012-09-11	2021-12-20	Medivation Prostate Therapeutics Llc	Preparaty enzalutamidu
US9977033B2 (en)	2012-09-11	2018-05-22	The Board Of Regents Of The University Of Texas System	Methods for assessing cancer recurrence
AU2013323861C1 (en) *	2012-09-26	2024-05-02	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
CN112353762A (zh)	2013-01-22	2021-02-12	霍夫曼-拉罗奇有限公司	具有改善的生物利用度的药物组合物
CN105246598B (zh)	2013-03-15	2019-09-13	太阳药业环球公司	乙酸阿比特龙酯制剂
WO2014167428A2 (en)	2013-04-10	2014-10-16	Shilpa Medicare Limited	Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
AU2014306698A1 (en)	2013-08-12	2016-01-28	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015116696A1 (en) *	2014-01-28	2015-08-06	Massachusetts Institute Of Technology	Combination therapies and methods of use thereof for treating cancer
KR20160113294A (ko) *	2014-02-05	2016-09-28	레크 파마슈티칼스 디.디.	안드로겐 수용체 길항제의 고체 제약 조성물
CN105980410B (zh)	2014-02-06	2020-02-28	豪夫迈·罗氏有限公司	白介素-2融合蛋白和其用途
TWI831347B (zh)	2014-08-08	2024-02-01	日商中外製藥股份有限公司	包含４環性化合物的非晶質體之固體分散體及製劑
EP4494636A3 (en)	2014-12-05	2025-04-30	Aragon Pharmaceuticals, Inc.	Anticancer compositions
CN115837010B (zh)	2014-12-05	2025-03-14	阿拉贡药品公司	抗癌组合物
MA41111B1 (fr) *	2014-12-05	2021-09-30	Aragon Pharmaceuticals Inc	Compositions anticancéreuses
CN109219437A (zh) *	2016-06-03	2019-01-15	阿拉贡药品公司	抗癌组合物

2015
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en active Application Filing
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/en active Active
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-07-19 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown

Also Published As

Publication number	Publication date
UA123538C2 (uk)	2021-04-21
JP6830892B2 (ja)	2021-02-17
MX381829B (es)	2025-03-13
KR102387089B1 (ko)	2022-04-14
CN106999432A (zh)	2017-08-01
US10285948B2 (en)	2019-05-14
HRP20211140T1 (hr)	2021-10-15
BR112017011726A2 (pt)	2017-12-26
EP3925598A1 (en)	2021-12-22
EP3226843B1 (en)	2021-05-26
MY192931A (en)	2022-09-15
CL2017001373A1 (es)	2018-01-05
MD3226843T2 (ro)	2021-10-31
MA41111B1 (fr)	2021-09-30
US11224575B2 (en)	2022-01-18
US20170360713A1 (en)	2017-12-21
DK3226843T3 (da)	2021-08-16
CA2969675C (en)	2023-06-06
PH12017500979A1 (en)	2017-11-27
US20190209477A1 (en)	2019-07-11
SI3226843T1 (sl)	2021-11-30
US11911511B2 (en)	2024-02-27
KR20170086658A (ko)	2017-07-26
AU2015358497B2 (en)	2021-04-29
ES2883187T3 (es)	2021-12-07
RS62421B1 (sr)	2021-10-29
SMT202100454T1 (it)	2021-09-14
CA2969675A1 (en)	2016-06-09
WO2016090105A1 (en)	2016-06-09
SG11201704386VA (en)	2017-06-29
PT3226843T (pt)	2021-07-07
EP3226843A1 (en)	2017-10-11
IL252325A0 (en)	2017-07-31
NI201700068A (es)	2017-09-11
CO2017005574A2 (es)	2017-09-29
EA201791251A1 (ru)	2017-11-30
JP2017536407A (ja)	2017-12-07
MX2017007206A (es)	2018-01-30
EP3925598B1 (en)	2025-02-12
LT3226843T (lt)	2021-08-10
TW201636019A (zh)	2016-10-16
CY1124504T1 (el)	2022-07-22
HUE054935T2 (hu)	2021-10-28
TWI709403B (zh)	2020-11-11
US20210308060A1 (en)	2021-10-07
CR20170218A (es)	2017-08-30
AR102925A1 (es)	2017-04-05
AU2015358497A1 (en)	2017-06-08

Publication	Publication Date	Title
IL279833A (en)	2021-01-31	Anti-cancer drugs
IL252324A0 (en)	2017-07-31	Anti-cancer drugs
IL252325A0 (en)	2017-07-31	Anti-cancer drugs
GB201618482D0 (en)	2016-12-14	Pharmaceutical compositions
GB201419257D0 (en)	2014-12-10	Pharmaceutical compositions
IL249553A0 (en)	2017-02-28	Pharmaceutical preparations
IL263157A (en)	2018-12-31	Anticancer compositions
GB201403017D0 (en)	2014-04-09	Composition
GB201703061D0 (en)	2017-04-12	Polyphenol compositions
GB201408167D0 (en)	2014-06-25	Compositions
IL251479A0 (en)	2017-05-29	components
IL250817A0 (en)	2017-04-30	pharmaceutical preparations
GB201420306D0 (en)	2014-12-31	Compositions
GB201403550D0 (en)	2014-04-16	Composition
GB201402648D0 (en)	2014-04-02	Composition
GB201419849D0 (en)	2014-12-24	Compositions
HUE036695T2 (hu)	2018-07-30	Ubidekarenon készítmény
GB201415634D0 (en)	2014-10-22	Novel compositions
GB201406863D0 (en)	2014-05-28	Compositions comprising variegin
GB202009707D0 (en)	2020-08-12	Anti-adherant botanical compositions
SG2014014872A (en)	2014-08-28	Pharmaceutical compositions
GB201408432D0 (en)	2014-06-25	Pharmaceutical compositions
GB201402487D0 (en)	2014-03-26	Composition